Treatment of cancer-related anemia with epoetin alfa: A review

Erminia Ferrario, Leonardo Ferrari, Paolo Bidoli, Daniela De Candis, Michele Del Vecchio, Sara De Dosso, Roberto Buzzoni, Emilio Bajetta

Research output: Contribution to journalArticle

Abstract

Erythropoietin (EPO) is a hematopoietic growth hormone that regulates survival, proliferation, and differentiation of erythroid progenitor cells. A reduction in tissue oxygenation stimulates EPO production, through a complex feedback mechanism. Patients with cancer-related anemia have an inadequate EPO response that is further impaired by cancer treatments such as chemotherapy. Cancer-related anemia substantially impairs patient functioning and may contribute to poor treatment outcomes. A significant number of studies demonstrates that treatment of anemia in cancer patients using recombinant human EPO (rHuEPO, epoetin alfa) significantly increases haemoglobin (Hb) levels, reduces transfusion requirements, and improves quality of life, particularly by relieving fatigue. Recent data also show that epoetin alfa therapy may improve cognitive function in patients receiving chemotherapy. In addition, the correction of anemia may prolong survival by enhancing tumor oxygenation, thus increasing tumor sensitivity to chemotherapy or radiation. The indicated dose of epoetin alfa is 150-300 IU/kg three times per week, but it is commonly dosed at 40,000-60,000 IU once weekly based on trial data and extensive clinical use. Determining the timing of initiation of epoetin alfa is a clinical judgement; however, data suggest that patient functioning declines and the risk of transfusion increases when the Hb level falls under 12 g/dL.

Original languageEnglish
Pages (from-to)563-575
Number of pages13
JournalCancer Treatment Reviews
Volume30
Issue number6
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Epoetin Alfa
Second Primary Neoplasms
Anemia
Erythropoietin
Neoplasms
Drug Therapy
Hemoglobins
Erythroid Precursor Cells
Survival
Cognition
Growth Hormone
Fatigue
Therapeutics
Quality of Life
Radiation

Keywords

  • Anemia
  • Cancer
  • Epoetin alfa
  • Haemoglobin
  • Malignancy
  • Treatment guidelines

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Ferrario, E., Ferrari, L., Bidoli, P., De Candis, D., Del Vecchio, M., De Dosso, S., ... Bajetta, E. (2004). Treatment of cancer-related anemia with epoetin alfa: A review. Cancer Treatment Reviews, 30(6), 563-575. https://doi.org/10.1016/j.ctrv.2004.04.005

Treatment of cancer-related anemia with epoetin alfa : A review. / Ferrario, Erminia; Ferrari, Leonardo; Bidoli, Paolo; De Candis, Daniela; Del Vecchio, Michele; De Dosso, Sara; Buzzoni, Roberto; Bajetta, Emilio.

In: Cancer Treatment Reviews, Vol. 30, No. 6, 10.2004, p. 563-575.

Research output: Contribution to journalArticle

Ferrario, E, Ferrari, L, Bidoli, P, De Candis, D, Del Vecchio, M, De Dosso, S, Buzzoni, R & Bajetta, E 2004, 'Treatment of cancer-related anemia with epoetin alfa: A review', Cancer Treatment Reviews, vol. 30, no. 6, pp. 563-575. https://doi.org/10.1016/j.ctrv.2004.04.005
Ferrario, Erminia ; Ferrari, Leonardo ; Bidoli, Paolo ; De Candis, Daniela ; Del Vecchio, Michele ; De Dosso, Sara ; Buzzoni, Roberto ; Bajetta, Emilio. / Treatment of cancer-related anemia with epoetin alfa : A review. In: Cancer Treatment Reviews. 2004 ; Vol. 30, No. 6. pp. 563-575.
@article{6ca6ce6372f04306983c4829a0834935,
title = "Treatment of cancer-related anemia with epoetin alfa: A review",
abstract = "Erythropoietin (EPO) is a hematopoietic growth hormone that regulates survival, proliferation, and differentiation of erythroid progenitor cells. A reduction in tissue oxygenation stimulates EPO production, through a complex feedback mechanism. Patients with cancer-related anemia have an inadequate EPO response that is further impaired by cancer treatments such as chemotherapy. Cancer-related anemia substantially impairs patient functioning and may contribute to poor treatment outcomes. A significant number of studies demonstrates that treatment of anemia in cancer patients using recombinant human EPO (rHuEPO, epoetin alfa) significantly increases haemoglobin (Hb) levels, reduces transfusion requirements, and improves quality of life, particularly by relieving fatigue. Recent data also show that epoetin alfa therapy may improve cognitive function in patients receiving chemotherapy. In addition, the correction of anemia may prolong survival by enhancing tumor oxygenation, thus increasing tumor sensitivity to chemotherapy or radiation. The indicated dose of epoetin alfa is 150-300 IU/kg three times per week, but it is commonly dosed at 40,000-60,000 IU once weekly based on trial data and extensive clinical use. Determining the timing of initiation of epoetin alfa is a clinical judgement; however, data suggest that patient functioning declines and the risk of transfusion increases when the Hb level falls under 12 g/dL.",
keywords = "Anemia, Cancer, Epoetin alfa, Haemoglobin, Malignancy, Treatment guidelines",
author = "Erminia Ferrario and Leonardo Ferrari and Paolo Bidoli and {De Candis}, Daniela and {Del Vecchio}, Michele and {De Dosso}, Sara and Roberto Buzzoni and Emilio Bajetta",
year = "2004",
month = "10",
doi = "10.1016/j.ctrv.2004.04.005",
language = "English",
volume = "30",
pages = "563--575",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Treatment of cancer-related anemia with epoetin alfa

T2 - A review

AU - Ferrario, Erminia

AU - Ferrari, Leonardo

AU - Bidoli, Paolo

AU - De Candis, Daniela

AU - Del Vecchio, Michele

AU - De Dosso, Sara

AU - Buzzoni, Roberto

AU - Bajetta, Emilio

PY - 2004/10

Y1 - 2004/10

N2 - Erythropoietin (EPO) is a hematopoietic growth hormone that regulates survival, proliferation, and differentiation of erythroid progenitor cells. A reduction in tissue oxygenation stimulates EPO production, through a complex feedback mechanism. Patients with cancer-related anemia have an inadequate EPO response that is further impaired by cancer treatments such as chemotherapy. Cancer-related anemia substantially impairs patient functioning and may contribute to poor treatment outcomes. A significant number of studies demonstrates that treatment of anemia in cancer patients using recombinant human EPO (rHuEPO, epoetin alfa) significantly increases haemoglobin (Hb) levels, reduces transfusion requirements, and improves quality of life, particularly by relieving fatigue. Recent data also show that epoetin alfa therapy may improve cognitive function in patients receiving chemotherapy. In addition, the correction of anemia may prolong survival by enhancing tumor oxygenation, thus increasing tumor sensitivity to chemotherapy or radiation. The indicated dose of epoetin alfa is 150-300 IU/kg three times per week, but it is commonly dosed at 40,000-60,000 IU once weekly based on trial data and extensive clinical use. Determining the timing of initiation of epoetin alfa is a clinical judgement; however, data suggest that patient functioning declines and the risk of transfusion increases when the Hb level falls under 12 g/dL.

AB - Erythropoietin (EPO) is a hematopoietic growth hormone that regulates survival, proliferation, and differentiation of erythroid progenitor cells. A reduction in tissue oxygenation stimulates EPO production, through a complex feedback mechanism. Patients with cancer-related anemia have an inadequate EPO response that is further impaired by cancer treatments such as chemotherapy. Cancer-related anemia substantially impairs patient functioning and may contribute to poor treatment outcomes. A significant number of studies demonstrates that treatment of anemia in cancer patients using recombinant human EPO (rHuEPO, epoetin alfa) significantly increases haemoglobin (Hb) levels, reduces transfusion requirements, and improves quality of life, particularly by relieving fatigue. Recent data also show that epoetin alfa therapy may improve cognitive function in patients receiving chemotherapy. In addition, the correction of anemia may prolong survival by enhancing tumor oxygenation, thus increasing tumor sensitivity to chemotherapy or radiation. The indicated dose of epoetin alfa is 150-300 IU/kg three times per week, but it is commonly dosed at 40,000-60,000 IU once weekly based on trial data and extensive clinical use. Determining the timing of initiation of epoetin alfa is a clinical judgement; however, data suggest that patient functioning declines and the risk of transfusion increases when the Hb level falls under 12 g/dL.

KW - Anemia

KW - Cancer

KW - Epoetin alfa

KW - Haemoglobin

KW - Malignancy

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=4344627592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344627592&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2004.04.005

DO - 10.1016/j.ctrv.2004.04.005

M3 - Article

C2 - 15325036

AN - SCOPUS:4344627592

VL - 30

SP - 563

EP - 575

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 6

ER -